Table 2.

Clinical Remission and Response Rates in Mexican-American Patients with Major Depression Who Received Desipramine or Fluoxetine^a

Treatment	Week	N	Remission				Response
			Rate %	RR	95% CI	P	Rate %	RR	95% CI	P
Longitudinal analysis of observed datab
Desipramine	1	111	0.9		Reference		1.7		Reference
Fluoxetine	1	120	1.7	1.90	0.17–21.08	0.600	3.3	1.87	0.35–10.10	0.466
Desipramine	2	105	3.7		Reference		11.9		Reference
Fluoxetine	2	113	3.5	0.95	0.24–3.72	0.936	9.4	0.79	0.37–1.68	0.534
Desipramine	3	99	3.9		Reference		15.2		Reference
Fluoxetine	3	110	5.5	1.40	0.40–4.84	0.598	14.9	0.98	0.52–1.83	0.945
Desipramine	4	97	4.4		Reference		21.6		Reference
Fluoxetine	4	106	10.2	2.33	0.81–6.69	0.117	30.7	1.42	0.90–2.26	0.135
Desipramine	5	86	11.9		Reference		36.0		Reference
Fluoxetine	5	100	19.9	1.67	0.84–3.33	0.143	50.2	1.39	1.00–1.94	0.049
Desipramine	6	82	21.4		Reference		44.0		Reference
Fluoxetine	6	95	25.0	1.17	0.68–2.00	0.575	59.4	1.35	1.02–1.79	0.036
Desipramine	7	75	31.3		Reference		59.0		Reference
Fluoxetine	7	93	51.0	1.63	1.11–2.39	0.012	75.1	1.27	1.04–1.56	0.020
Desipramine	8	74	43.1		Reference		60.7		Reference
Fluoxetine	8	92	59.1	1.37	1.01–1.87	0.046	79.7	1.31	1.09–1.59	0.005
				HR	95% CI	P		HR	95% CI	P
Survival analysis of observed datac
Desipramine	time to event	112			Reference				Reference
Fluoxetine	time to event	120		1.57	0.98–2.51	0.060		2.01	1.40–3.13	<0.001

^aRates were estimated after adjustment for gender, age and baseline score; RR=Relative Risk; HR=Hazard Ratio.

^bGeneralized estimating equation (GEE) model for repeated measures analysis included all available observations.

^cCox regression model for survival analysis included all subjects with event (response or remission) or right censoring time.